Skye Bioscience, Inc. (NASDAQ:SKYE) on Monday shared interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab.Skye Phase 2a clinical trial (NCT06577090) in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy).Interim Data SummaryThe blinded extension of the CBeyond study for combination cohorts ...

22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab dosesWeight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone during 13-week off-therapy follow-up, demonstrating durability advantageStrong safety and tolerability profile maintained — no serious adv ...

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled "Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model" at Keystone’s conference, Obesity Therapeutics: Unlocking Benefi ...

Core Insights - Skye Bioscience is presenting research on its CB1-inhibitor antibody, nimacimab, at an upcoming conference focused on obesity therapeutics [1] - The presentation will explore nimacimab's efficacy alone and in combination with tirzepatide, as well as its potential as a maintenance therapy after discontinuation of tirzepatide [1][4] Company Overview - Skye Bioscience is a clinical-stage biotechnology company dedicated to developing new therapeutic pathways for obesity and metabolic health disorders [3] - The company is focused on creating next-generation molecules that modulate G-protein coupled receptors, aiming for first-in-class therapeutics with clinical and commercial differentiation [3] Product Details - Nimacimab is a first-in-class, peripherally-restricted monoclonal antibody that inhibits the CB1 receptor without penetrating the central nervous system, potentially reducing neuropsychiatric side effects [2] - It acts independently of the GLP-1 pathway and has shown additive effects when combined with incretin-based therapies in both preclinical and clinical studies [2] Clinical Trials - Skye is conducting a Phase 2a clinical trial for nimacimab in obesity, which also assesses its combination with a GLP-1R agonist, Wegovy® [3] - The trial is registered under ClinicalTrials.gov with the identifier NCT06577090 [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on January 16, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Skye securities between November 4, 2024, and October 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by the January 16, 2026 deadline to serve as lead plaintiff, representing other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone, and has consistently ranked in the top 4 for securities class action settlements since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements about Skye's business and prospects, specifically regarding the effectiveness of nimacimab and its clinical, regulatory, and commercial prospects [5]. - The claims suggest that when the true information became public, investors suffered damages due to the misleading statements made by the defendants [5].

NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its drug nimacimab during the class period from November 4, 2024, to October 3, 2025 [7]. Allegation Details - The lawsuit claims that Skye's management misrepresented the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [7]. - Specific allegations include that nimacimab was less effective than claimed, leading to misleading public statements about its potential [7]. Stock Impact - Following the announcement of disappointing clinical trial results on October 6, 2025, Skye's stock price dropped by $2.85 per share, or 60%, closing at $1.90 per share [7]. Next Steps - Investors who purchased Skye securities during the class period and suffered losses are encouraged to contact Bragar Eagel & Squire for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 16, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in securities litigation [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Company Overview - Skye Bioscience, Inc. is a San Diego-based biotech company focused on developing therapies for obesity and metabolic diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025, and they have until January 16, 2026, to seek appointment as lead plaintiff [1][2]. - The complaint alleges that the company overstated the efficacy of nimacimab and exaggerated its clinical success and commercial potential [3]. Financial Impact - Following the release of topline results from the 26-week Phase 2a CBeyond study on October 6, 2025, which indicated that nimacimab did not meet its primary weight-loss endpoint compared to placebo, Skye's share price plummeted by 60%, falling from $4.75 to $1.90 per share [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to allegations of misleading statements about the company's lead product candidate, nimacimab, which was claimed to be less effective than represented [1][2]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [1]. - Allegations include that the defendants made materially false and misleading statements about nimacimab's effectiveness and overstated its clinical, regulatory, and commercial prospects [1]. - Shareholders are encouraged to register for the class action and can do so without any cost or obligation [2]. Group 2: Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - The deadline to seek lead plaintiff status is January 16, 2026 [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Skye Bioscience, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its lead product candidate, nimacimab, which was claimed to be less effective than previously communicated [3][4]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [3]. - Allegations include that the company overstated the clinical, regulatory, and commercial prospects of nimacimab, leading to materially false and misleading public statements [3]. Group 2: Shareholder Actions - Shareholders who purchased SKYE shares during the class period are encouraged to register for the class action, with a deadline of January 16, 2026, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Group 3: Law Firm's Role - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investors' rights against deceit and fraud [5]. - The firm aims to recover losses incurred by investors due to the alleged misleading statements by Skye Bioscience [5].